CYTOCHLOR

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H12ClN3O4
Molecular Weight	261.662
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC(=O)N(C=C1Cl)[C@H]2C[C@H](O)[C@@H](CO)O2

InChI

InChIKey=NGGRGTWYSXYVDK-RRKCRQDMSA-N

InChI=1S/C9H12ClN3O4/c10-4-2-13(9(16)12-8(4)11)7-1-5(15)6(3-14)17-7/h2,5-7,14-15H,1,3H2,(H2,11,12,16)/t5-,6+,7+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C9H12ClN3O4
Molecular Weight	261.662
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugbank.ca/drugs/DB12383
Curator's Comment: The description was created based on several sources, including https://clinicaltrials.gov/ct2/show/record/NCT00521183 | https://www.ncbi.nlm.nih.gov/pubmed/2432451 | https://clinicaltrials.gov/ct2/show/record/NCT00077051 | https://www.ncbi.nlm.nih.gov/pubmed/14751833

Cytochlor is a radio-sensitizing pyrimidine nucleoside with potential antineoplastic activity. Cytochlor is metabolized first to a phosphate derivative, CldCMP, by the enzyme deoxycytidine kinase and then to the active uracyl derivative, CldUMP, by the enzyme dCMP deaminase. CldUMP, the active metabolite, incorporates into DNA and, upon exposure to radiation, induces the formation of uracil radicals and double-strand DNA breaks. Cytochlor has been used in trials studying the treatment of Head and Neck Cancer and Brain and Central Nervous System Tumors.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 278 Target ID: CHEMBL2311221 Sources: https://link.springer.com/chapter/10.1007/978-3-319-13278-5_15	Crosslinking Agent 81

Conditions

Condition	Modality	Targets	Highest Phase	Product
Brain and central nervous system tumors 1 Sources: https://clinicaltrials.gov/ct2/show/NCT00521183	Primary		Phase I 428	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	DCK 1 CDD 1

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CDD 1	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/6291452/	yes [Km 1.1 uM]
DCK 1	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/6291452/	yes [Km 56 uM]

Sourcing

Vendor/Aggregator	ID	URL
BOC Sciences	32387-56-7	http://www.bocsci.com/description.asp?cas=32387-56-7
BioSynth	W-202328	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/W-202328
Norris Pharm	NSZB-A194536
eMolecules	29257240	https://orderbb.emolecules.com/search/#?query=29257240
mcule	MCULE-8189824669	https://mcule.com/MCULE-8189824669/

PubMed

Title	Date	PubMed
Potent inhibition of HhaI DNA methylase by the aglycon of 2-(1H)-pyrimidinone riboside (zebularine) at the GCGC recognition domain.	2003 Dec	14751833

Patents

Sample Use Guides

In Vivo Use Guide

Patients receive cytochlor IV (50 mg/m2/day) and tetrahydrouridine (720 mg/m2/day) IV over 5 minutes on 3 days in week 1 and on days 1-5 in weeks 2 and 3.

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:29:48 GMT 2023` Edited by `admin` on `Fri Dec 15 15:29:48 GMT 2023`
Record UNII	J14D49ZN55
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CYTOCHLOR

Common Name

English

5-CHLORODEOXYCYTIDINE

Systematic Name

English

5-CLDC

Common Name

English

CLDC

Common Name

English

5-CHLORO-2'-DEOXYCYTIDINE

Systematic Name

English

NSC-371331

Code

English

CYTIDINE, 5-CHLORO-2'-DEOXY-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C798